Joe Salvani, MicroCap Investor, speaks about Navidea Biopharmaceuticals (NAVB)
One Response to “Joe Salvani, MicroCap Investor, speaks about Navidea Biopharmaceuticals (NAVB)”
Leave a Reply
You must be logged in to post a comment.
FINANCIAL MODELS
FEATURES
CP REPORTS
CP Reports
- The Goldman Guide: Why The Market Hates Us… June 18, 2013 by Rob Goldman
- Market Alert: Wall Street Rumblings # CLIX June 17, 2013 by Ray Dirks
- Sam Seiden Market Commentary: The White Space… June 16, 2013 by Sam Seiden
- The Goldman Guide: The Future of Small Stock Investors…June 10, 2013 by Rob Goldman
- Market Alert: Wall Street Rumblings # CLVIII June 10, 2013 by Ray Dirks
- Sam Seiden Market Commentary: Is Trading Really An Art? June 4, 2013
admin
21. Sep, 2012
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, CFT and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit http://www.navidea.com.